TY - JOUR
T1 - Somatostatin receptor imaging and theranostics
T2 - Current practice and future prospects
AU - Park, Sonya
AU - Parihar, Ashwin Singh
AU - Bodei, Lisa
AU - Hope, Thomas A.
AU - Mallak, Nadine
AU - Millo, Corina
AU - Prasad, Kalpna
AU - Wilson, Don
AU - Zukotynski, Katherine
AU - Mittra, Erik
N1 - Publisher Copyright:
COPYRIGHT ß 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based g-scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy–based Krenning score for PRRT eligibility. Also, to date, the role of SSTR PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR PET in all aspects of neuroendocrine neoplasms, including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR PET–based response assessment. We also provide a standardized reporting template for SSTR PET with a brief discussion.
AB - A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based g-scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy–based Krenning score for PRRT eligibility. Also, to date, the role of SSTR PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR PET in all aspects of neuroendocrine neoplasms, including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR PET–based response assessment. We also provide a standardized reporting template for SSTR PET with a brief discussion.
KW - Ga-DOTANOC
KW - Ga-DOTATATE
KW - Neuroendocrine neoplasms
KW - Peptide receptor radionuclide therapy
KW - SSTR
KW - Somatostatin
UR - http://www.scopus.com/inward/record.url?scp=85118948087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118948087&partnerID=8YFLogxK
U2 - 10.2967/jnumed.120.251512
DO - 10.2967/jnumed.120.251512
M3 - Article
C2 - 34301785
AN - SCOPUS:85118948087
SN - 0161-5505
VL - 62
SP - 1323
EP - 1329
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 10
ER -